Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
Purchase Agreement
On December 6, 2018, Amyris, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain private investors (the “Purchasers”) relating to the sale of $60.0 million aggregate principal amount of senior convertible notes (the “Notes”) that are convertible into shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”). The Purchase Agreement includes customary representations, warranties and covenants by the Company. In addition, the Purchase Agreement prohibits the Company, subject to certain exceptions, from (i) disposing of any Common Stock or securities convertible into or exchangeable for shares of Common Stock during the period commencing on the date of Purchase Agreement and continuing through the later of (A) the date 90 days after the Closing (as defined below) and (B) the date 30 days after the Registration Statement (as defined below) is declared effective and (ii) effecting or entering into an agreement to effect any issuance involving a Variable Rate Transaction (as defined in the Purchase Agreement) for so long as the Notes remain outstanding.
The closing of the issuance and sale of the Notes (the “Closing”) is expected to occur on or about December 10, 2018, subject to customary closing conditions. The net proceeds from the sale of the Notes, after deducting estimated offering expenses payable by the Company and placement agent and advisory fees, are expected to be approximately $56.2 million. The Company intends to use the majority of the net proceeds from the sale of the Notes to repay the Company’s 9.50% Convertible Senior Notes due 2019 and/or the Company’s 6.50% Convertible Senior Notes due 2019 (the terms of which were previously reported in Note 4, “Debt” in Part II, Item 8 of the Company’s Annual Report on 10-K for the fiscal year ended December 31, 2017, which disclosure is incorporated herein by reference) and the balance for working capital and other general corporate purposes.
Notes
The Notes will be general unsecured obligations of the Company. Unless earlier converted or redeemed, the Notes will mature on the third anniversary of issuance, subject to the rights of the holdersto extend the maturity date in certain circumstances. The Notes will be convertible from time to time, at the election of theholders, into shares of Common Stockat an initial conversion price of$6.32per share. The conversion price will be subject to adjustment inthe event of any stock split, reverse stock split, recapitalization, reorganization or similar transaction. The Company will have the option, upon prior notice to the holders, to settle any conversion of the Notes in cash.
The Notes willbe payable in equal monthly installments beginning April 1, 2019 (each, an “Installment Date”), in either cash at 108% of such installment amount or, at the Company’s option, subject to the satisfaction of certain equity conditions (the “Equity Conditions”), in shares of Common Stock at a discount to the then-current market price, subject to a price floor (the “Installment Conversion Price”). The holders will have the right, upon notice to the Company, to defer all or any portion of any installment amount to a future Installment Date. In addition, if the Company elects to pay any installments in shares of Common Stock, the holders of the Notes will have the right to accelerate amounts outstanding under their Notes during such month up to an aggregate of three times the relevant installment amount.
The Notes will bear interest at a rate of 6% per annum, payable quarterly until the first Installment Date, and then at each Installment Date thereafter. Interest on the Notes may be paid in either cash or, at the Company’s option, subject to the satisfaction of the Equity Conditions, shares of Common Stock at the Installment Conversion Price.
The Notes contain customary terms and covenants, including (i) a restriction on the Company’s ability to incur additional indebtedness, (ii) certain events of default, after which the holders may require the Company toredeem all or any portion of their Notes in cash at a price equal to the greater of (A)125% of the amount being redeemed and (B)the intrinsic value of the shares of Common Stock underlying the amount being redeemed, and (iii) certain other events, after which the holders may convert all or any portion of the Notes at a discount to the Installment Conversion Price.
In the event of a Fundamental Transaction (as defined in the Notes), holders of the Notes may require the Company to redeem all or any portion of their Notes at a price equal to the greater of(i)125% of the amount being redeemed and (ii)a premium to the intrinsic value of the shares of Common Stock underlyingthe amount being redeemed.
Notwithstanding the foregoing, the holders will not have the right to convert any portion of a Note, and the Company will not have the option to pay any amount in shares of Common Stock, if (a) the holder, together with its affiliates, would beneficially own in excess of 4.99% (or such other percentage as determined by the holder and notified to the Company in writing, not to exceed 9.99%, provided that any increase of such percentage will not be effective until 61 days after notice thereof) of the number of shares of Common Stock outstanding immediately after giving effect to such conversion or payment, as applicable (the “Ownership Limitation”), or (b) the aggregate number of shares issued with respect to the Notes (and any other transaction aggregated for such purpose) after giving effect to such conversion or payment, as applicable, would exceed 15,271,047 shares of Common Stock (the “Exchange Cap”). In the event that (i) the Company is prohibited from issuing any shares of Common Stock under the Notes as a result of the Ownership Limitation (other than in connection with a conversion of Notes), such shares shall be held in abeyance (and the related principal amount of the Notes reinstated) until the holder shall notify the Company and elect to receive such shares without exceeding the Ownership Limitation, and (ii) the Company is prohibited from issuing any shares of Common Stock under the Notes as a result of the Exchange Cap, the Company will pay cash in lieu of any shares that would otherwise be deliverable in excess of the Exchange Cap.
Registration Rights Agreement
In connection with the offering of the Notes under the Purchase Agreement, the Company has agreed to enter into a registration rights agreement, to be dated as of the Closing (the “Registration Rights Agreement”), with the Purchasers. Under the Registration Rights Agreement, the Company would be obligated to file a registration statement on Form S-3 (except if the Company is then ineligible to register such shares for resale on Form S-3, in which case such registration shall be on such other form available to register such shares for resale as a secondary offering) (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”) registering the resale of all of the shares of Common Stock issuable to the terms of the Notes, including, without limitation, upon conversion or otherwise (the “Registrable Securities”) under the Securities Act of 1933, as amended (the “Securities Act”), within 30 days following the Closing. In addition, the Company is obligated to have the Registration Statement declared effective by the SEC by the date that is 60 days after the Closing (or, in the event the SEC reviews and has comments on the Registration Statement, the 90th calendar day following the Closing). In the event that the Registration Statement is not filed or declared effective within the foregoing time frames, or if thereafter, subject to certain exceptions, the Registration Statement is not effective for any reason or the prospectus contained therein is not available for use by the holders, Company shall pay to each holder an amount in cash equal to 2% of such holder’s original principal amount of Notes on the date of such failure and thereafter on every 30 day anniversary thereof until such failure is cured or no longer prevents the holders from freely disposing of their Registrable Securities.
The foregoing description of the Purchase Agreement, the Notes and the Registration Rights Agreement is qualified in its entirety by reference to the Securities Purchase Agreement, the Form of Senior Convertible Note and the Form of Registration Rights Agreement, which are filed hereto as Exhibit 10.1, Exhibit 4.1 and Exhibit 4.2, respectively, and are incorporated herein by reference.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
| Item 1.01 | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The information contained in Item 1.01 above is incorporated herein by reference.
| Item 1.01 | Unregistered Sales of Equity Securities. |
The information contained in Item 1.01 above is incorporated herein by reference.
The Notes (including the shares of Common Stock underlying the Notes) will be issued in a private placement to the exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D promulgated under the Securities Act.
| Item 1.01 | Regulation FD Disclosure. |
On December 7, 2018, the Company issued a press release regarding the matters discussed herein, a copy of which is attached hereto as Exhibit 99.1.
The information in this Item 1.01 and Exhibit 99.1 attached hereto is furnished to the rules and regulations of the SEC and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 1.01 | Financial Statements and Exhibits. |
(d)Exhibits
The following exhibits are filed herewith:
Forward-Looking Statements
This report contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding the timing of the Closing, the amount of proceeds to be received by the Company from the sale of the Notes and the uses thereof, and related matters. These statements are subject to risks and uncertainties, including the failure of closing conditions to be satisfied, and actual results may differ materially from these statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
AMYRIS, INC. ExhibitEX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”),…To view the full exhibit click here
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.